Wellstat Therapeutics Corporation (rights to uridine triacetate)
M&A
STATUS
Asset Purch.
LATEST DEAL TYPE
1
FINANCING ROUNDS
Description
Distribution rights in the United States of uridine triacetate drug. The drug is used for treating patients at risk of serious toxicity following an overdose of 5-flourouracil.
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Other Commercial Services
Acquirer
Primary Office
- 930 Clopper Road
- Gaithersburg, MD 20878
- United States
Wellstat Therapeutics Corporation (rights to uridine triacetate) Valuation and Funding
| Deal Type | Date | Amount | Post-Val | Valuation/ EBITDA |
Debt | Status |
|---|
This information is reserved for PitchBook Platform users. To explore Wellstat Therapeutics Corporation (rights to uridine triacetate)‘s full profile, request access.
Request full access to PitchBookWellstat Therapeutics Corporation (rights to uridine triacetate) Former Investors
| Investor Name | Investor Type | Holding | Participating Rounds | Investor Since | Board Seat | Contact Info |
|---|
This information is reserved for PitchBook Platform users. To explore Wellstat Therapeutics Corporation (rights to uridine triacetate)‘s full profile, request access.
Request full access to PitchBook